CLINICAL_TRIALS
trial_result
· 2013-12-23
Clinical Trial Update: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma [Phase 3]
Summary
Phase 3 trial evaluating lanreotide as the primary treatment for acromegaly due to pituitary macroadenoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2013-12-23